RETRACTED: Long noncoding RNA neuroblastoma-associated transcript 1 gene inhibits malignant cellular phenotypes of bladder cancer through miR-21/SOCS6 axis (Retracted article. See vol. 13, 2022)

被引:0
作者
Liu, Zhongyuan [1 ]
Xie, Dalong [2 ]
Zhang, Hui [1 ]
机构
[1] China Med Univ, Shengjing Hosp, Dept Urinary Surg, Shenyang 110004, Liaoning, Peoples R China
[2] China Med Univ, Coll Basic Med Sci, Dept Anat, Shenyang 110122, Liaoning, Peoples R China
来源
CELL DEATH & DISEASE | 2018年 / 9卷
基金
中国国家自然科学基金;
关键词
UP-REGULATION; CHEMOTHERAPY RESISTANCE; CARCINOMA-CELLS; PROLIFERATION; INVASION; TARGET; SOCS6; ANGIOGENESIS; PROGRESSION; METASTASIS;
D O I
暂无
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Bladder cancer (BC) is one of the most common tumors in the urinary system. Noncoding RNAs are considered to take part in cellular phenotypes and are emerging as diagnostic and prognostic biomarkers of BC. The aim of this study is to investigate the clinical significance of neuroblastoma- associated transcript 1 (NBAT1) gene and its effects on malignant cellular phenotypes in BC. NBAT1 gene was low-expressed in BC tissues and cell lines and its low-expression was related with high pathological grade and metastasis of BC. Upregulation of NBAT1 gene depressed cell viability and invasiveness of KK47 and T24 cells and arrested KK47 and T24 cells at G1 stage. In addition, NBAT1 could target silence the expression of miR-21-5p in RNA-induced silencing complex-dependent manner. KK47 and T24 cells with miR-21-5p knockdown showed reduced cell viability, G1-stage arrest, and depressed invasiveness. MiR-21-5p mediates the regulatory effects of NBAT1 on malignant cellular phenotypes of BC cells. Moreover, SOCS6 gene was a target gene of miR-21-5p, and miR-21-5p modulated malignant cellular phenotypes of KK47 and T24 cells through targeted silencing of SOCS6. In conclusion, low-expression of NBAT1 is associated with the progress and metastasis of BC, and NBAT1 inhibits malignant cellular phenotypes through miR-21-5p/SOCS6 axis in BC. Our findings help to elucidate the tumorigenesis of BC, and future study will provide a novel therapeutic target for BC.
引用
收藏
页数:13
相关论文
共 38 条
  • [31] YUAN D, 2018, CURR CANC DRUG TARGE
  • [32] Long noncoding RNA GAS5 inhibits malignant proliferation and chemotherapy resistance to doxorubicin in bladder transitional cell carcinoma
    Zhang, Hui
    Guo, Yan
    Song, Yongsheng
    Shang, Chao
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (01) : 49 - 55
  • [33] miR-21 Downregulated TCF21 to Inhibit KISS1 in Renal Cancer
    Zhang, Hui
    Guo, Yan
    Shang, Chao
    Song, YongSheng
    Wu, Bin
    [J]. UROLOGY, 2012, 80 (06) : 1298 - +
  • [34] Silence of Long Noncoding RNA NEAT1 Inhibits Malignant Biological Behaviors and Chemotherapy Resistance in Gastric Cancer
    Zhang, Jiale
    Zhao, Bochao
    Chen, Xiuxiu
    Wang, Zhenning
    Xu, Huimian
    Huang, Baojun
    [J]. PATHOLOGY & ONCOLOGY RESEARCH, 2018, 24 (01) : 109 - 113
  • [35] Long noncoding RNA LINC00152 as a novel predictor of lymph node metastasis and survival in human cancer: a systematic review and meta-analysis
    Zhang, Jiaming
    Yin, Minuo
    Huang, Junming
    Lv, Zhengtao
    Liang, Shuang
    Miao, Xiaoao
    Huang, Fang
    Zhao, Yingchao
    [J]. CLINICA CHIMICA ACTA, 2018, 483 : 25 - 32
  • [36] MiR-16-1 Targeted Silences Far Upstream Element Binding Protein 1 to Advance the Chemosensitivity to Adriamycin in Gastric Cancer
    Zhao, Danyi
    Zhang, Yang
    Song, Lei
    [J]. PATHOLOGY & ONCOLOGY RESEARCH, 2018, 24 (03) : 483 - 488
  • [37] Novel long noncoding RNA GACAT3 promotes colorectal cancer cell proliferation, invasion, and migration through miR-149
    Zhou, Weiwei
    Wang, Lei
    Miao, Yu
    Xing, Rongge
    [J]. ONCOTARGETS AND THERAPY, 2018, 11 : 1543 - 1552
  • [38] MiR-21-5p, miR-34a, and human telomerase RNA component as surrogate markers for cervical cancer progression
    Zhu, Yue
    Han, Ying
    Tian, Tian
    Su, Peihong
    Jin, Guan
    Chen, Juan
    Cao, Yungui
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 2018, 214 (03) : 374 - 379